Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and pressure-volume hemodynamics. Key takeaway: Video Kinematics Predict Donor Heart Function. Article Links: Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. (Journal of the American College of Cardiology) Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. (JACC. Heart failure) Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. (JACC. Heart failure) Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. (JACC. Heart failure) Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Full episode page: https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/ Featured Articles Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171219 Summary: The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients. Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. Journal: JACC. Heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171248 Summary: This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension. Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. Journal: JACC. Heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171251 Summary: This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study’s primary objective is to assess C.R.D.-740’s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction. Article 4: Serum Magnesium and the Effect